Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE plus oral semaglutide in early Alzheimer's disease
CTR20212849Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by Novo Nordisk. Started Dec 2021; status: terminated.
02
Drugs
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on CTR20212849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212849.